Statin use and mortality in gout: A general population-based cohort study

Area of Science:

• Cardiovascular epidemiology
• Pharmacological interventions
• Public health research

Background:

• Gout is a significant risk factor for cardiovascular disease and premature mortality.
• Understanding interventions that improve survival in gout patients is crucial for public health.

Purpose of the Study:

• To investigate the potential survival benefits of statin therapy in a general population of patients with gout.
• To assess the association between statin initiation and all-cause mortality in gout patients.

Main Methods:

• A large-scale, population-based incident user cohort study was conducted using UK general population data (1999-2014).
• Time-stratified propensity score matching was employed to compare statin initiators and non-initiators.
• Hazard ratios and mortality rate differences were estimated using Cox proportional hazard and additive hazard models, respectively.

Main Results:

• Statin initiation was associated with a 16% lower relative risk of all-cause mortality (HR=0.84) in gout patients.
• Statin users experienced 7.7 fewer deaths per 1000 person-years compared to non-users.
• The mortality benefit of statins was more significant in patients without a history of circulatory disease (p=0.02 for interaction).

Conclusions:

• Statin initiation is associated with reduced all-cause mortality in patients with gout.
• The findings suggest that statins may offer a substantial survival advantage, particularly for gout patients without pre-existing circulatory conditions.
• Optimizing statin use could play a key role in mitigating premature mortality in the gout population.